Nasal spray to treat Covid-19 enters phase 2 trials

October 07, 2021 2 min read

Nasal spray to treat Covid-19 enters phase 2 trials

One of our Stoic VC investee companies, ENA Respiratory, that offers huge potential in how we might deal with the pandemic globally.

A nasal spray offering users protection from Covid-19 could soon be employed as another line of defence against the virus, as encouraging results from a preliminary trial of the solution trigger a second phase of studies.

The revolutionary spray could provide almost immediate protection against coronavirus and influenza by activating natural immunity in the nose and throat, where respiratory viruses enter the body. The treatment, which uses the compound INNA-051, is being researched by Hunter Medical Research Institute and University of Newcastle respiratory researchers, who are developing the treatment for Australian biotech company Ena Respiratory.

“We discovered that INNA-051 is very effective at priming the airways to more rapidly and effectively respond to a viral infection,” associate professor Nathan Bartlett, from the University of Newcastle and head of HMRI’s Viral Immunology and Respiratory Disease Group, said. “HMRI’s proof of concept data was instrumental in ensuring the treatment was ideally placed to be tested against the virus that causes Covid-19.”

Professor Bartlett began work with Ena Respiratory prior to the pandemic to target the primary entry site for viral respiratory infections, including flu and common colds.

Later pre-clinical studies found the treatment was also effective in treating Covid-19.

INNA-051 would work to complement a vaccine, particularly where inoculation is likely to be less effective such as the elderly, patients with chronic lung disease and the immunocompromised.

“As we continue to combat current and emerging Covid-19 variants, there is a significant need for convenient therapies that boost protection in at-risk populations,” Ena Respiratory chief Christophe Demaison said. “By stimulating the innate immune response, we hope to create an extra line of defence against Covid-19 and other respiratory viral infections.”

The company is pushing ahead with phase-two trials across several countries to begin in January.

https://www.theaustralian.com.au/science/nasal-spray-to-treat-covid19-enters-phase-2-trials/news-story/a09cf897e316559f5ddb20c4b18ccb3d



Also in In the Media

3 ways universities can improve their chances of commercialising research
3 ways universities can improve their chances of commercialising research

January 28, 2022 2 min read

Stoic Venture Capital Partner Geoff Waring said there are a few initiatives universities could undertake to further improve their chances of attracting investors to commercialise their research.
Customers Can Own A Piece Of Smart Helmet Startup Forcite Helmets
Customers Can Own A Piece Of Smart Helmet Startup Forcite Helmets

November 22, 2021 2 min read

Forcite previously secured funding from Australian research and commercialization fund Uniseed and Atlas Advisors Australia. 
Liquid metal helps convert CO2 into battery, manufacturing resources
Liquid metal helps convert CO2 into battery, manufacturing resources

October 25, 2021 1 min read

US and Australia-based researchers have discovered a cheap new way to capture and convert CO2 emissions using liquid gallium.